https://www.selleckchem.com/products/gsk650394.html Lorcaserin was associated with a significantly greater proportion of reports of valvular disorders (ROR = 4.39; 95% CI 2.72-5.07). None of the antiobesity drugs were associated with a safety signal for valvulopathy, PH, or other cardiovascular events. CONCLUSIONS Our analyses revealed a signal for valvular disorders with lorcaserin and did not detect a safety signal for other cardiovascular events with recently approved antiobesity drugs. Further research is needed to explore and validate this signal.OBJECTIVE To evaluate associations between maternal antidepressant use during pregnancy and hypoglycemia in term neonates. STUDY DESIGN We conducted a prospective comparative cohort study of neonates of ≥37 weeks' gestation. Neonates whose mothers used antidepressants during pregnancy were compared with randomly selected cohort of neonates whose mothers did not use antidepressants. Blood glucose was measured at 24 ± 2 h after birth. Hypoglycemia was defined as blood glucose level less then 2.6 mmol/L. We needed 60 patients in each group to reject the null hypothesis. RESULTS Mean gestational ages were 39 vs. 40 weeks (p  less then  0.01) and birthweights were 3250 vs. 3360 g (p = 0.08) for antidepressant-exposed vs. -unexposed neonates. There were no significant differences between groups in odds of hypoglycemia (4/59 exposed vs. 2/61 unexposed; adjusted relative risk 1.73; 95% confidence interval [CI] 0.37-8.92) or mean blood glucose levels. CONCLUSIONS Maternal antidepressant use during pregnancy was not associated with neonatal hypoglycemia at 24 h of age.OBJECTIVE To assess the cardiac function and prevalence of congenital heart defects (CHD) in twin-twin transfusion syndrome (TTTS) survivors. STUDY DESIGN Prospective follow-up of TTTS pregnancies treated with laser surgery (2015-2018). Echocardiography was performed 1 day and 1 month after birth (corrected for prematurity). Results were compared with a control gro